Patient Profile 1: A Patient With HER2+ Metastatic BC Treated With T-DXd who Develops ILD

Video

After reviewing the historical use of ADCs, panelists discuss the first patient profile of HER2+ metastatic breast cancer managed with trastuzumab deruxtecan.

Recent Videos
Image of a woman with glasses wearing a striped blouse and a black sweater in front of an Oncology Nursing News branded backdrop
Image of Kayle Freeman, DNP, APRN, FNP-C, in a video call with an Oncology Nursing News border around the frame
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Image of Pattie Jakel, MN, RN, AOCN, in front of a blue watercolor Oncology Nursing News backdrop
Image of Jessie Desir, PhD, RN, AMB-BC, OCN, in a video call with a blue and gold Oncology Nursing News border surrounding the frame.
Medium closeup shot of a women in front of a dark blue background with graphics that read "All in Against Cancer" and "Ochsner Health"
Smiling woman in front of a blue video call background with logos that say "All in Against Cancer" and "Ochsner Health" above her
woman in front of a dark blue background for Oschner Health
woman in front of a blue background with dark hair
image of a woman in front of a blue background with a navy top
Related Content
Line illustration of an IV drip in gold on a dark blue background

FDA Approves Denosumab Biosimiliars for Prior Authorized Indications

Tim Cortese
March 13th 2025
Article

Two denosumab biosimilars have been approved by the FDA for all previously approved uses for the reference drugs in cancers and osteoporosis.

The Vitals

ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

Lindsay Fischer
October 31st 2023
Podcast

Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.

Anatomical diagram of a person with the gastrointestinal tract highlighted in orange

OS Benefit With T-DXd in Unresectable/Metastatic HER2+ Gastric/GEJ Adenocarcinoma

Chris Ryan
March 6th 2025
Article

T-DXd delivered an OS benefit for patients with unresectable or metastatic HER2-positive gastric and GEJ adenocarcinoma following trastuzumab-based treatment.

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Improving The Rate Of Accurate Inflammatory Breast Cancer Diagnoses

Lindsay Fischer
October 2nd 2023
Podcast

Ryan Tamargo, NP, AONCP, discusses the launch of an online inflammatory breast cancer scoring system tool.

green background with dark blue text indicating FDA and green text indicating approved with a checkmark

FDA Approves Tislelizumab Combo for Advanced ESCC

Ashling Wahner;Kristi Rosa
March 4th 2025
Article

The FDA approved tislelizumab-jsgr (Tevimbra) with platinum chemotherapy as a first-line treatment for adults with PD-L1-positive, unresectable or metastatic esophageal squamous cell carcinoma.

Blue image of a person with the esophagus and stomach highlighted in orange

Perioperative FLOT Improves Survival in Resectable Esophageal Carcinoma

Bridget Hoyt
February 24th 2025
Article

Perioperative chemotherapy improved survival compared with preoperative chemoradiotherapy in managing esophageal cancer.